ABCL.US Abcellera Biologics Inc

Healthcare Biotechnology USA Stocks
11.62 USD
Close of Nov 13, 2026
2.75 15.02
Market cap
USD 3.80B
P/E
-
P/B
3.67x
ROE
-17.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ABCL.US undervalued?

Graham number

The Graham number of Abcellera Biologics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Abcellera Biologics Inc fundamental analysis

No fundamental analysis for Abcellera Biologics Inc yet.

Abcellera Biologics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Abcellera Biologics Inc

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The …

Full company profile